Department of Tumor Biology, Leibniz-Institute for Experimental Virology, Virus Genomics, Hamburg, Germany.
J Biol Chem. 2013 Aug 9;288(32):22993-3008. doi: 10.1074/jbc.M113.456293. Epub 2013 Jun 29.
Using a retrovirus-mediated cDNA expression cloning approach, we identified the grainyhead-like 2 (GRHL2) transcription factor as novel protooncogene. Overexpression of GRHL2 in NIH3T3 cells induced striking morphological changes, an increase in cell proliferation, anchorage-independent growth, and tumor growth in vivo. By combining a microarray analysis and a phylogenetic footprinting analysis with various biochemical assays, we identified the epidermal growth factor receptor family member Erbb3 as a novel GRHL2 target gene. In breast cancer cell lines, shRNA-mediated knockdown of GRHL2 expression or functional inactivation of GRHL2 using dominant negative GRHL2 proteins induces down-regulation of ERBB3 gene expression, a striking reduction in cell proliferation, and morphological and phenotypical alterations characteristic of an epithelial-to-mesenchymal transition (EMT), thus implying contradictory roles of GRHL2 in breast carcinogenesis. Interestingly, we could further demonstrate that expression of GRHL2 is directly suppressed by the transcription factor zinc finger enhancer-binding protein 1 (ZEB1), which in turn is a direct target for repression by GRHL2, suggesting that the EMT transcription factors GRHL2 and ZEB1 form a double negative regulatory feedback loop in breast cancer cells. Finally, a comprehensive immunohistochemical analysis of GRHL2 expression in primary breast cancers showed loss of GRHL2 expression at the invasive front of primary tumors. A pathophysiological relevance of GRHL2 in breast cancer metastasis is further demonstrated by our finding of a statistically significant association between loss of GRHL2 expression in primary breast cancers and lymph node metastasis. We thus demonstrate a crucial role of GRHL2 in breast carcinogenesis.
我们使用逆转录病毒介导的 cDNA 表达克隆方法,鉴定出颗粒头样蛋白 2(GRHL2)转录因子为新的原癌基因。在 NIH3T3 细胞中过表达 GRHL2 会引起显著的形态变化,增加细胞增殖、锚定非依赖性生长和体内肿瘤生长。通过结合微阵列分析和系统进化足迹分析以及各种生化测定,我们鉴定出表皮生长因子受体家族成员 Erbb3 为 GRHL2 的新靶基因。在乳腺癌细胞系中,shRNA 介导的 GRHL2 表达敲低或使用显性负性 GRHL2 蛋白对 GRHL2 的功能失活会诱导 ERBB3 基因表达下调、细胞增殖显著减少以及具有上皮-间充质转化(EMT)特征的形态和表型改变,从而暗示 GRHL2 在乳腺癌发生中具有相反的作用。有趣的是,我们还可以进一步证明 GRHL2 的表达被转录因子锌指增强子结合蛋白 1(ZEB1)直接抑制,而 ZEB1 反过来又是 GRHL2 抑制的直接靶标,这表明 EMT 转录因子 GRHL2 和 ZEB1 在乳腺癌细胞中形成了一个双重负反馈调节环。最后,对原发性乳腺癌中 GRHL2 表达的综合免疫组织化学分析显示,原发性肿瘤侵袭前沿的 GRHL2 表达缺失。我们发现原发性乳腺癌中 GRHL2 表达缺失与淋巴结转移之间存在统计学显著关联,进一步证明了 GRHL2 在乳腺癌转移中的病理生理相关性。因此,我们证明了 GRHL2 在乳腺癌发生中的关键作用。